IGF1 and ischemia: While these neuroprotective effects are also well documented for other neurodegenerative and neurotraumatic conditions, including amyotrophic lateral sclerosis and ischemia (Bassil et al., 2014; Bernhard et al., 2016; Rodriguez-Perez et al., 2016; Bianchi et al., 2017; Labandeira-Garcia et al., 2017), reductions in IGF-1-mediated signaling, on the other hand, have been shown to delay amyloid-β proteotoxicity in mice (Cohen et al., 2009; Gontier et al., 2015).